0001140361-24-024333.txt : 20240503 0001140361-24-024333.hdr.sgml : 20240503 20240503160609 ACCESSION NUMBER: 0001140361-24-024333 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wotton Paul K CENTRAL INDEX KEY: 0001300997 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 24913038 MAIL ADDRESS: STREET 1: C/O ANTARES PHARMA, INC. STREET 2: 707 EAGLEVIEW BOULEVARD, SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml FORM 4 X0508 4 2024-05-01 0000887359 Vericel Corp VCEL 0001300997 Wotton Paul K C/O VERICEL CORPORATION 64 SIDNEY STREET CAMBRIDGE MA 02139 true false Common Stock 2024-05-01 4 M 0 3200 A 30002 D Restricted Stock Unit 2024-05-01 4 M 0 3200 A Common Stock 3200 0 D Stock Option (Right to Buy) 47.08 2024-05-01 4 A 0 8000 0 A 2034-05-01 Common Stock 8000 8000 D Restricted Stock Unit 2024-05-01 4 A 0 3200 0 A Common Stock 3200 3200 D The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. Upon the vesting of RSUs granted to the Reporting Person on May 3, 2023, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023. No expiration date for this type of award. The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. /s/ Sean Flynn, as Attorney-in-Fact for Paul Wotton 2024-05-03